Vistagen Therapeutics Inc. (VSTA) 10.0000 $VSTA
Follow the Gileader
M2 - Thu May 07, 8:26AM CDT
Companies mentioned in this article: Gilead Sciences (NASDAQ: GILD), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Synageva BioPharma Corp. (NASDAQ: GEVA), VistaGen (OTCQB: VSTA), Juno Therapeutics, Inc. (JUNO) and Fate Therapeutics, Inc. (FATE)
GEVA: 211.50 (-1.10), GILD: 109.30 (+0.56), ALXN: 160.56 (-1.13), JUNO: 43.37 (-1.52)
Gilead Sciences Knocks it out of the Park, but does that mean that Biopharma is Undervalued?
M2 - Mon May 04, 7:40AM CDT
After taking a beating to close out April, with iShares Nasdaq Biotechnology (NASDAQ: IBB) losing nearly 10% off the mid-month highs, the biotech sector may have gotten the shot in the arm it need for the next leg up. By generating $2.94 a share profits, more than doubling the previous year's quarterly profits, on $7.6 billion revenues, a better than 50% improvement in year-over-year revenues, Gilead Sciences (NASDAQ: GILD) destroyed its earnings and 2015 sales guidance to the $28-29 billion range. By doing so, Gilead may have just kick started the next biopharma bull run.
GILD: 109.30 (+0.56), PFE: 33.99 (+0.05), IBB: 355.61 (+0.02), GSK: 44.77 (-0.22), CAPN: 4.66 (-0.05)
BioPharmas are running the FDA Fast Track to Success
M2 - Wed Apr 22, 4:06AM CDT
Biopharma listings tend to reward investors early and often. One of my favorite plays in this sector is the 505(b)(2), an FDA provision that's best known as the fast track announcement. Since these announcements are often made before the street is familiar with the company, or the developmental treatment, the biopharma premium is not priced into the listings. Fast Track designation may be awarded to medicines that are intended to treat a serious or life-threatening disease, or condition, and demonstrate the potential to address unmet medical needs. In addition to reducing the development and approval timeline, the provision can also reduce the financial outlay needed to commercialize the respective products.
HZNP: 29.03 (+0.63), ABIO: 0.84 (unch), ORPN: 5.95 (-0.04), DYAX: 26.35 (+0.22)
VistaGen and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder
Marketwired - Tue Feb 17, 8:04AM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company developing innovative medicine for depression and conditions involving the central nervous system (CNS), has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. National Institute of Mental Health (NIMH), part of the U.S. National Institutes of Health (NIH). Under the CRADA, VistaGen and the NIMH will collaborate on an NIH-sponsored Phase 2 clinical study of AV-101, VistaGen's orally-active NMDA receptor modulator, in subjects with Major Depressive Disorder (MDD). MDD is a widespread and debilitating mental disorder affecting millions worldwide, including nearly 7% of U.S. adults.
Dr. Gerard Sanacora Joins VistaGen's Clinical and Scientific Advisory Board
Marketwired - Thu Feb 05, 9:53AM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company developing innovative medicine for depression and conditions involving the central nervous system, has added Gerard Sanacora PhD, MD, Professor of Psychiatry at the Yale School of Medicine and Director of the Yale Depression Research Program, to its Clinical and Scientific Advisory Board. Dr. Sanacora will focus on Phase 2 and Phase 3 clinical development of AV-101, VistaGen's orally-active NMDA receptor modulator for treating Major Depressive Disorder (MDD). AV-101 is a unique prodrug candidate that produces, in the brain, 7-chlorokynurenic acid (7-Cl-KYNA), one of the most potent and selective antagonists of the required glycine-binding site of the NMDA receptor, which results in down-regulation of NMDA signaling.
VistaGen Signs Letter of Intent With National Institute of Mental Health for NIH-Sponsored Phase 2 Clinical Study of AV-101 in Major Depressive Disorder
Marketwired - Wed Nov 19, 2:42PM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company focused on innovative medicine for depression, cancer and diseases and disorders involving the central nervous system (CNS), has signed a Letter of Intent to enter into a Cooperative Research and Development Agreement (CRADA) with the National Institute of Mental Health (NIMH), part of the National Institutes of Health (NIH), to collaborate on a NIMH-sponsored Phase 2 clinical study of VistaGen's lead drug candidate, AV-101, in Major Depressive Disorder, one of the most common mental disorders in the U.S.
VistaGen Receives Notice of Allowance for Canadian Patent Further Expanding Stem Cell Technology Platform
Marketwire - Tue Aug 19, 8:30AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug rescue, drug discovery and regenerative medicine, today announces that the Canadian Intellectual Property Office has issued a Notice of Allowance for Canadian Patent Application No. 2,487,058, entitled "Mesoderm and Definitive Endoderm Cell Populations." This patent, which is licensed exclusively to VistaGen by the Icahn School of Medicine at Mount Sinai in New York, will further expand VistaGen's intellectual property portfolio for pluripotent stem cell culture systems that produce human cells of the endoderm lineage, including liver, lung, pancreas, parathyroid and thyroid cells.
VistaGen approves one for-20 reverse split reverse stock split
M2 - Thu Aug 14, 3:05AM CDT
Stem cell company VistaGen Therapeutics (OTCQB:VSTA) reported on Wednesday the authorisation of a one for-20 reverse split of its common stock.
VistaGen Announces Reverse Stock Split
Marketwire - Wed Aug 13, 5:21PM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a stem cell company focused on drug rescue, drug discovery and regenerative medicine, announced today that will implement a 1-for-20 reverse split of its common stock effective at the opening of trading on August 14, 2014. At that time, VistaGen's common stock will trade on a split-adjusted basis under new CUSIP number 92840H202 and temporary symbol "VSTAD," with the "D" appended to signify that the reverse stock split has occurred. VistaGen's trading symbol will revert to "VSTA" after approximately 20 trading days.
VistaGen Therapeutics, Inc. - Product Pipeline Review - 2014
M2 - Fri Jul 25, 3:32AM CDT
Summary
VistaGen Therapeutics, Inc. (VSTA) - Product Pipeline Analysis
M2 - Fri Jul 11, 3:24AM CDT
Summary
VistaGen Receives Notice of Allowance for Canadian Patent Expanding Stem Cell Technology Platform
Marketwire - Mon Jun 16, 8:30AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug rescue and regenerative medicine, today announces that the Canadian Intellectual Property Office has issued a Notice of Allowance for Canadian patent No. 2,684,022, entitled "Mesoderm and Definitive Endoderm Cell Populations." This patent, which is licensed exclusively to VistaGen by the Icahn School of Medicine at Mount Sinai in New York, will expand VistaGen's intellectual property portfolio for pluripotent stem cell culture systems that produce human cells of the endoderm lineage, including liver, lung, pancreas, parathyroid and thyroid cells.
Follow the Gileader
M2 - Thu May 07, 8:26AM CDT
Companies mentioned in this article: Gilead Sciences (NASDAQ: GILD), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Synageva BioPharma Corp. (NASDAQ: GEVA), VistaGen (OTCQB: VSTA), Juno Therapeutics, Inc. (JUNO) and Fate Therapeutics, Inc. (FATE)
GEVA: 211.50 (-1.10), GILD: 109.30 (+0.56), ALXN: 160.56 (-1.13), JUNO: 43.37 (-1.52)
Gilead Sciences Knocks it out of the Park, but does that mean that Biopharma is Undervalued?
M2 - Mon May 04, 7:40AM CDT
After taking a beating to close out April, with iShares Nasdaq Biotechnology (NASDAQ: IBB) losing nearly 10% off the mid-month highs, the biotech sector may have gotten the shot in the arm it need for the next leg up. By generating $2.94 a share profits, more than doubling the previous year's quarterly profits, on $7.6 billion revenues, a better than 50% improvement in year-over-year revenues, Gilead Sciences (NASDAQ: GILD) destroyed its earnings and 2015 sales guidance to the $28-29 billion range. By doing so, Gilead may have just kick started the next biopharma bull run.
GILD: 109.30 (+0.56), PFE: 33.99 (+0.05), IBB: 355.61 (+0.02), GSK: 44.77 (-0.22), CAPN: 4.66 (-0.05)
BioPharmas are running the FDA Fast Track to Success
M2 - Wed Apr 22, 4:06AM CDT
Biopharma listings tend to reward investors early and often. One of my favorite plays in this sector is the 505(b)(2), an FDA provision that's best known as the fast track announcement. Since these announcements are often made before the street is familiar with the company, or the developmental treatment, the biopharma premium is not priced into the listings. Fast Track designation may be awarded to medicines that are intended to treat a serious or life-threatening disease, or condition, and demonstrate the potential to address unmet medical needs. In addition to reducing the development and approval timeline, the provision can also reduce the financial outlay needed to commercialize the respective products.
HZNP: 29.03 (+0.63), ABIO: 0.84 (unch), ORPN: 5.95 (-0.04), DYAX: 26.35 (+0.22)
VistaGen and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder
Marketwired - Tue Feb 17, 8:04AM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company developing innovative medicine for depression and conditions involving the central nervous system (CNS), has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. National Institute of Mental Health (NIMH), part of the U.S. National Institutes of Health (NIH). Under the CRADA, VistaGen and the NIMH will collaborate on an NIH-sponsored Phase 2 clinical study of AV-101, VistaGen's orally-active NMDA receptor modulator, in subjects with Major Depressive Disorder (MDD). MDD is a widespread and debilitating mental disorder affecting millions worldwide, including nearly 7% of U.S. adults.
Dr. Gerard Sanacora Joins VistaGen's Clinical and Scientific Advisory Board
Marketwired - Thu Feb 05, 9:53AM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company developing innovative medicine for depression and conditions involving the central nervous system, has added Gerard Sanacora PhD, MD, Professor of Psychiatry at the Yale School of Medicine and Director of the Yale Depression Research Program, to its Clinical and Scientific Advisory Board. Dr. Sanacora will focus on Phase 2 and Phase 3 clinical development of AV-101, VistaGen's orally-active NMDA receptor modulator for treating Major Depressive Disorder (MDD). AV-101 is a unique prodrug candidate that produces, in the brain, 7-chlorokynurenic acid (7-Cl-KYNA), one of the most potent and selective antagonists of the required glycine-binding site of the NMDA receptor, which results in down-regulation of NMDA signaling.
VistaGen Signs Letter of Intent With National Institute of Mental Health for NIH-Sponsored Phase 2 Clinical Study of AV-101 in Major Depressive Disorder
Marketwired - Wed Nov 19, 2:42PM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company focused on innovative medicine for depression, cancer and diseases and disorders involving the central nervous system (CNS), has signed a Letter of Intent to enter into a Cooperative Research and Development Agreement (CRADA) with the National Institute of Mental Health (NIMH), part of the National Institutes of Health (NIH), to collaborate on a NIMH-sponsored Phase 2 clinical study of VistaGen's lead drug candidate, AV-101, in Major Depressive Disorder, one of the most common mental disorders in the U.S.
VistaGen Receives Notice of Allowance for Canadian Patent Further Expanding Stem Cell Technology Platform
Marketwire - Tue Aug 19, 8:30AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug rescue, drug discovery and regenerative medicine, today announces that the Canadian Intellectual Property Office has issued a Notice of Allowance for Canadian Patent Application No. 2,487,058, entitled "Mesoderm and Definitive Endoderm Cell Populations." This patent, which is licensed exclusively to VistaGen by the Icahn School of Medicine at Mount Sinai in New York, will further expand VistaGen's intellectual property portfolio for pluripotent stem cell culture systems that produce human cells of the endoderm lineage, including liver, lung, pancreas, parathyroid and thyroid cells.
VistaGen approves one for-20 reverse split reverse stock split
M2 - Thu Aug 14, 3:05AM CDT
Stem cell company VistaGen Therapeutics (OTCQB:VSTA) reported on Wednesday the authorisation of a one for-20 reverse split of its common stock.
VistaGen Announces Reverse Stock Split
Marketwire - Wed Aug 13, 5:21PM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a stem cell company focused on drug rescue, drug discovery and regenerative medicine, announced today that will implement a 1-for-20 reverse split of its common stock effective at the opening of trading on August 14, 2014. At that time, VistaGen's common stock will trade on a split-adjusted basis under new CUSIP number 92840H202 and temporary symbol "VSTAD," with the "D" appended to signify that the reverse stock split has occurred. VistaGen's trading symbol will revert to "VSTA" after approximately 20 trading days.
VistaGen Therapeutics, Inc. - Product Pipeline Review - 2014
M2 - Fri Jul 25, 3:32AM CDT
Summary
VistaGen Therapeutics, Inc. (VSTA) - Product Pipeline Analysis
M2 - Fri Jul 11, 3:24AM CDT
Summary
VistaGen Receives Notice of Allowance for Canadian Patent Expanding Stem Cell Technology Platform
Marketwire - Mon Jun 16, 8:30AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug rescue and regenerative medicine, today announces that the Canadian Intellectual Property Office has issued a Notice of Allowance for Canadian patent No. 2,684,022, entitled "Mesoderm and Definitive Endoderm Cell Populations." This patent, which is licensed exclusively to VistaGen by the Icahn School of Medicine at Mount Sinai in New York, will expand VistaGen's intellectual property portfolio for pluripotent stem cell culture systems that produce human cells of the endoderm lineage, including liver, lung, pancreas, parathyroid and thyroid cells.
